Entrada Therapeutics : Corporate Presentation

Corporate Presentation

September 2023

DISCLAIMER

This presentation includes express and implied "forward-looking statements." Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward- looking statements contained in this presentation include, but are not limited to, statements about our product development activities and clinical trials, our regulatory filings and approvals, statements related to our ability to initiate and recruit for a healthy volunteer trial for ENTR-601-44 in the United Kingdom with first subject dosed in September 2023, expectations regarding the timing of data from our Phase 1 trial for ENTR-601-44 in the second half of 2024, the ability to resolve the clinical hold for ENTR-601-44 and subsequent activities, expectations regarding the timing or content of any update regarding our regulatory filings, expectations regarding the safety and therapeutic benefits of ENTR-601-44, our ability to develop and advance our current and future product candidates and discovery programs, our ability to establish and maintain collaborations or strategic relationships, our ability to raise additional funding, the rate and degree of market acceptance and clinical utility of our product candidates, the potential of our EEV product candidates and EEV platform, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates, including our Vertex partnership for ENTR-701, our collaborators' ability to protect our intellectual property for our products, and the sufficiency of our cash resources through 2025. By their nature, these statements are subject to numerous risks and uncertainties, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

2

September 2023

ENTRADA'S MISSION

Treating Devastating Diseases With

Intracellular Therapeutics

3

ENTRADA AT A GLANCE

Entrada is leveraging its Endosomal Escape Vehicle platform (EEV™️) to create a diverse and expanding development portfolio of RNA-, antibody- and enzyme-based therapeutics

• Advancing new therapeutic options for people living with Duchenne muscular dystrophy (DMD)
• • Lead DMD program (ENTR-601-44): First participant expected to be dosed in September 2023
  • Additional programs focus on clinical candidate, ENTR-601-45, with discovery efforts underway in exons 50 and 51
• Transformative Vertex partnership for the development of myotonic dystrophy, type 1 (DM1)
• • $224M upfront payment and $26M equity investment; Up to $485M for the achievement of certain milestones, plus royalties; Four-year global research collaboration
  • Entrada is responsible for preclinical development; Vertex is responsible for global development, regulatory, manufacturing and commercialization
• Expanding our commitment to non-neuromuscular disease programs
• • EEV's unique mechanism of action is designed to enable delivery of various moieties into organs and tissues
• Strong financial position with cash runway through 2025*
• Experienced leadership team and Board of Directors, supported by leading biotech investors

September 2023

4

*Assumes existing cash, cash equivalents, marketable securities, together with Vertex collaboration ongoing research support and achievement of certain milestones.

LEADERSHIP TEAM AND BOARD OF DIRECTORS

Dipal Doshi	Natarajan Sethuraman, PhD	Nerissa Kreher, MD	Nathan Dowden
President and CEO	Chief Scientific Officer	Chief Medical Officer	Chief Operating Officer

Kory Wentworth, CPA	Kerry Robert	Jared Cohen, PhD, JD	Karla MacDonald
Chief Financial Officer	Senior Vice President, People	General Counsel	Chief Corporate Affairs Officer

Board of Directors

Kush Parmar, MD, PhD

Managing Partner

5AM Ventures

(Board Chairman)

Peter S. Kim, PhD

Virginia and D.K. Ludwig Prof. of Biochemistry Stanford University

Gina Chapman

President and CEO

CARGO Therapeutics

John Crowley

Executive Chairman

Amicus Therapeutics

Mary Thistle

Industry Leader and Independent

Board Member

Bernie Zeiher, MD

Industry Leader and Independent

Board Member

Dipal Doshi

President and CEO

5

September 2023